Soluble guanylate cyclase subunit beta-1 (sGCβ1)

Soluble guanylate cyclase subunit beta-1 is an intracellular enzyme subunit that forms a heterodimer with an alpha subunit to create soluble guanylate cyclase (sGC), the principal nitric oxide receptor in mammalian cells[6][1][2][3][5]. The beta-1 subunit houses the heme prosthetic group within its N-terminal H-NOX domain, conferring the enzyme’s ability to bind nitric oxide. NO-driven activation of sGC increases the catalytic conversion of GTP to cyclic GMP (cGMP), a key second messenger mediating smooth muscle relaxation, vasodilation, inhibition of platelet aggregation, and other cardiovascular effects[1][2][3][4][6][5]. Drugs such as riociguat, vericiguat, and cinaciguat target this pathway, either by stimulating or directly activating the beta-1 subunit, making sGCβ1 a validated therapeutic enzyme for diseases associated with impaired NO/cGMP signaling, particularly pulmonary hypertension and heart failure[3][7]. The enzyme’s pivotal role in vascular function places it at the center of numerous physiological and pathophysiological processes[2][5].

Other names

Guanylate cyclase soluble subunit beta-1sGC beta-1GUCY1B1 (gene symbol)Beta-1 subunit of soluble guanylate cyclaseSoluble guanylyl cyclase beta-1

Stimulation of cGMP production via activation or stabilization of the sGC catalytic domain; Allosteric activation by binding stimulators to the beta-1 H-NOX/CC interface; Direct activation by NO binding to the heme on beta-1 subunit, promoting conformational activation of catalytic function